Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2018-05-01
2019-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective. Observe the characteristics of pain, coping models and the perception of quality of life in patients with congenital coagulopathies.
Study design. Observational, cross-sectional and multi-center study. Method. 80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain. The study variables and measurement instruments used will be: pain perception (numerical pain scale, Tampa Scale of kinesiophobia and Pain Catastrophizing Scale); perception of quality of life (Short Form -36 questionnaires); anxiety (State-Trait Anxiety Questionnaire); coping strategies (Coping Strategy Questionnaire); and disease perception (Illness behaviour questionnaire and Revised Illness Perception Questionnaire). A descriptive statistical analysis of the dependent and independent variables will be carried out. In the same way, the correlations between the variables and the characteristics of the subjects will be analyzed according to age, the type of coagulopathy and the degree of sequelae.
Expected results. Observe the characteristics of pain, its coping models and its implication in the quality of life in patients with congenital coagulopathies, and evaluate the independent variables related to the perception of pain.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy
NCT06960499
Post-traumatic Arthritis Associated With Joint Injury
NCT01792791
Evaluation of Cognitive Behavioral Therapy for Long-term Pain in Rheumatic Disease, Including Validation of AE-FS
NCT06413914
Pain in Juvenile Arthritis
NCT07217782
Chronic Non-inflammatory Pains in Rheumatopediatrics
NCT03740347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Main objective: to observe the characteristics of pain, its coping models and its implication in the quality of life in patients with congenital coagulopathies. Secondary objectives: to evaluate the degree of kinesiofobia and catastrophism in patients with congenital coagulopathies; analyze the perception of quality of life, of disease and of anxiety in patients with hemophilia and von Willebrand's disease of age; and to identify the ingestion and administration of analgesic drugs in patients with hemophilia or von Willebrand's disease for the control of pain.
Design of the investigation Describe the type of study, methodology, research variables Cross-sectional and multicentric observational study, carried out in patients with congenital coagulopathies, with the aim of knowing the characteristics of pain, its coping strategies and its implications for quality of life.
Collection of information Instruments and data collection process
* Numerical scale of pain. The patient assigns pain a numerical value between 0 and 10. With this scale pain is considered a simple one-dimensional concept and is measured only according to its intensity. The scale is discrete, not continuous.
* Short Form 36 Health Survey (SF-36). Health questionnaire that measures the quality of life related to health. Generic instrument consisting of 36 questions, covering 8 dimensions (physical functioning, physical role, body pain, general health, vitality, social functioning, emotional role and mental health of the patient).
* State-Trait Anxiety Inventory (STAI). Generic instrument that assesses the current level of anxiety and the predisposition of the person to respond to stress. It consists of two sections that let you know how you feel at a certain time and how you feel in general. The score for each scale can range from 0-30, indicating higher scores, higher levels of anxiety.
* Tampa Scale of kinesiophobia (TSK-11SV). Through this scale the fear of movement of the patients included in the study will be evaluated. This self-report measure contains 17 items on fear of movement and recurrence of a new lesion. Four of the items have a negative wording and carry an inverse notation. The scores of the different items evaluated are added to give a total score, where the highest values reflect a greater fear of injury or relapse of the same.
* Pain catastrophizing scale (PCS). Self-administered scale of 13 items used to assess the 3-dimensional pain-mapping construct: rumination, magnification and hopelessness. Low scores indicate a low catastrophization, and high values, high catastrophization.
* Coping Strategies Questionnaire (CSQ). Questionnaire composed of 42 items grouped in 7 scales of 6 items each. Each item is scored according to a scale of 7 points: deviation of attention, reinterpretation of pain sensations, ignorance of pain sensations, self-assertive coping, prayer and hope, catastrophism and increased level of activity.
Subjects of the study Number and characteristics of the sample. The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document. On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments.
It is expected to recruit a total of 80 patients for inclusion in the study. The sample size is justified with respect to the prevalence of patients with hemophilia (2039 patients with hemophilia A and B in Spain). Based on the established selection criteria (n = 678, according to the census of the Spanish Federation of Hemophilia) the sample size at the national level would be 151, with a level of confidence or 95% confidence and an expected proportion of dropouts from the fifteen%. Thus, for the 6 regions of Spain where the study will be developed, a sample of 80 patients is established for the established study period (April to December 2018).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational group
80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.
The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.
On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments.
Observational group
The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:
* Numerical scale of pain
* Short Form 36 Health Survey \[SF-36\].
* State-Trait Anxiety Inventory \[STAI\].
* Tampa Scale of Kinesiophofia \[TSK-11SV\].
* Pain catastrophizing scale \[PCS\].
* Coping Strategies Questionnaire \[CSQ\].
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational group
The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:
* Numerical scale of pain
* Short Form 36 Health Survey \[SF-36\].
* State-Trait Anxiety Inventory \[STAI\].
* Tampa Scale of Kinesiophofia \[TSK-11SV\].
* Pain catastrophizing scale \[PCS\].
* Coping Strategies Questionnaire \[CSQ\].
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients over 18 years of age
* Patients in a prophylactic or on demand regimen with FVIII / FIX concentrates
* Patients that have accepted the informed consent document.
Exclusion Criteria
* Patients without capacity to walk autonomously or with orthosis
* Patients without access to digital media to complement the measuring instruments.
18 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Real Fundación Victoria Eugenia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rubén Cuesta-Barriuso, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rubén Cuesta Barriuso
Role: PRINCIPAL_INVESTIGATOR
Royal Victoria Eugenia Foundation
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
He-Pain Situation
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.